Proshares UltraPro NASDAQ Biotechnology
UBIO
UBIO was delisted on the 27th of March, 2020.
8 hedge funds and large institutions have $2.16M invested in Proshares UltraPro NASDAQ Biotechnology in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.
11% less funds holding
Funds holding: 9 → 8 (-1)
48% less capital invested
Capital invested by funds: $4.17M → $2.16M (-$2.01M)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
99% less call options, than puts
Call options by funds: $2K | Put options by funds: $384K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$49.4K |
| 2 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$40.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$1.61M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$790K |
| 3 |
VF
Virtu Financial
New York
|
-$549K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$58.7K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
-$4.04K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $961K | -$549K | -13,593 | -38% |
|
|
2
Jane Street
New York
| $610K | -$1.61M | -40,000 | -74% |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $318K | -$58.7K | -1,455 | -17% |
|
|
4
UBS Group
Zurich,
Switzerland
| $144K | +$49.4K | +1,224 | +60% |
|
|
5
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $44K | +$40.4K | +1,000 | New |
|
6
Morgan Stanley
New York
| $36K | -$4.04K | -100 | -11% |
|
|
LTFS
7
Ladenburg Thalmann Financial Services
Miami,
Florida
| $32K | – | – | – |
|
|
AIM
8
Anchor Investment Management
Columbia,
South Carolina
| $12.2K | – | – | – |
|
|
9
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$790K | -23,744 | Closed |
|
|
CG
10
Cutler Group
San Francisco,
California
| – | -$4.04K | -100 | Closed |
|
UBIO Hedge Fund Activity: Q3 2018 in Review
8 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Proshares UltraPro NASDAQ Biotechnology (UBIO) for Q3 2018, worth a combined $2.16M — down 48% from $4.17M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of UBIO and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $49.4K. The largest seller was Jane Street, cutting an estimated $1.61M.
- 8 institutional investors held Proshares UltraPro NASDAQ Biotechnology (UBIO) as of Q3 2018, down from 9 in Q2 2018.
- Funds reported $2.16M of Proshares UltraPro NASDAQ Biotechnology stock for Q3 2018, down 48% quarter-over-quarter.
- 1 fund opened new Proshares UltraPro NASDAQ Biotechnology positions in Q3 2018 and 2 closed out, a net change of -1 holder.
- The largest Proshares UltraPro NASDAQ Biotechnology buyer in Q3 2018 was UBS Group, an estimated $49.4K added.
- The largest Proshares UltraPro NASDAQ Biotechnology seller in Q3 2018 was Jane Street, an estimated $1.61M sold.
Based on aggregated 13F filings for Q3 2018.